Anti-SIRPα antibody therapy can stimulate an influx of tumor-infiltrating NK cells and CD8+ T-cells, as well as induce DC activation and promote T-cell effector function when used in combination with anti-PD-1 antibodies (36). Here, SIRPA is linked to neoplasm.